Aptevo Therapeutics Inc (APVO)

Currency in USD
2.1449
-0.0251(-1.16%)
Real-time Data·
APVO Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Trading near 52-week Low
APVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.09922.1931
52 wk Range
2.0992381.1000
Key Statistics
Prev. Close
2.17
Open
2.15
Day's Range
2.0992-2.1931
52 wk Range
2.0992-381.1
Volume
42.97K
Average Volume (3m)
2.29M
1-Year Change
-99.3%
Book Value / Share
-20.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APVO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
420.0000
Upside
+19,481.33%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Aptevo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Aptevo Therapeutics Inc Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Compare APVO to Peers and Sector

Metrics to compare
APVO
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.4x−0.5x
PEG Ratio
-0.010.00
Price/Book
−5.3x2.5x2.6x
Price / LTM Sales
-10.0x3.3x
Upside (Analyst Target)
-85.9%43.5%
Fair Value Upside
Unlock1.9%6.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 420.0000
(+19,481.33% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-4.39 / -0.28
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

APVO Income Statement

People Also Watch

40.40
BMNR
+5.02%
6.6999
CYN
+1.67%
3.150
HCTI
-4.83%
22.780
SBET
+2.89%

FAQ

What Stock Exchange Does Aptevo Therapeutics Trade On?

Aptevo Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Aptevo Therapeutics?

The stock symbol for Aptevo Therapeutics is "APVO."

What Is the Aptevo Therapeutics Market Cap?

As of today, Aptevo Therapeutics market cap is 7.93M.

What Is Aptevo Therapeutics's Earnings Per Share (TTM)?

The Aptevo Therapeutics EPS (TTM) is -745.27.

From a Technical Analysis Perspective, Is APVO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Aptevo Therapeutics Stock Split?

Aptevo Therapeutics has split 4 times.

How Many Employees Does Aptevo Therapeutics Have?

Aptevo Therapeutics has 37 employees.

What is the current trading status of Aptevo Therapeutics (APVO)?

As of 07 Aug 2025, Aptevo Therapeutics (APVO) is trading at a price of 2.14, with a previous close of 2.17. The stock has fluctuated within a day range of 2.10 to 2.19, while its 52-week range spans from 2.10 to 381.10.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.